GILD

Gilead Sciences may be overvalued by about 22% after its Liver Meeting 2026 update. The company highlighted new data on its liver disease drugs Livdelzi and Hepcludex, drawing fresh attention to its pipeline.

Gilead and Roche are focusing on early‑stage biotech assets rather than full buyouts this week. They are investing in inflammation, cancer therapies, antibody‑drug conjugates, and next‑generation T‑cell engagers.

HOUSTON, October 23, 2026--Building on decades of holding pharmaceutical companies responsible for dangerous products and unlawful business practices, The Lanier Law Firm played a pivotal role supporting Texas Attorney General Ken Paxton in securing a $45 million settlement with Gilead Sciences, Inc. Announced on Oct.

Gilead is spending $1.28 billion to develop HCXT‑2001, a potential rival to PepStar’s Icotyde. The drug will be tested both as a monotherapy and in combination with Gilead’s IBD hopeful, emvistegrast.

FOSTER CITY, Calif., October 22, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company.

Gilead agreed to acquire PepStar Therapeutics’ oral IL‑23R inhibitor program for $1.275 billion. The deal includes the lead asset HCXT‑2001 and expands Gilead’s portfolio in inflammatory disease.

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.